However, the modern management of AML has been significantly improved by the availability of novel targeted agents, such as an anti-CD33 monoclonal antibody, a BCL-2 inhibitor (venetoclax), FLT3 inhibitors (midostaurin, quizartinib, and gilteritinib), and IDH1/2 inhibitors (ivosidenib and enasidenib). Here, BCL2 is linked to acute myeloid leukemia.